Top Life Science Financial Services Providers in Latin America
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Life Science Financial Services Providers in Latin America
Life Science Financial Services News
Trial Growth in Latin America Raises Demand for Specialist Insurance Brokerage
Wednesday, July 29, 2026
Clinical research insurance brokerage services in Latin America are gaining stronger relevance as sponsors, CROs and medical device developers expand trial activity across the region. Latin America offers patient access, experienced investigators and competitive research costs, but sponsors also need insurance programs that satisfy local regulators and ethics committees before studies can begin. The region’s clinical research market is expanding. One 2026 market estimate values the Latin America clinical trials market at USD 4.44 billion in 2026 and projects it to reach USD 11.86 billion by 2036, at a CAGR of 10.32 percent. Another outlook expects the Latin America pharmac
Country-Specific Insurance Rules Make Local Brokerage Expertise Critical
Wednesday, July 29, 2026
Clinical research insurance brokerage services in Latin America are being shaped by the fact that trial insurance requirements vary by country and cannot always be solved through a single global policy. Sponsors conducting multi-country studies must coordinate coverage across local regulators, ethics committees, hospitals and research sites. Countries from Latin America like Brazil, Mexico, Argentina, Chile and Colombia typically demand compulsory insurance for any clinical trials performed in their respective regions. The limit of insurance is usually based on international norms and risks involved. One insurance-cost analysis describes typical limits in the USD 1 million to US
Complex Trial Models Increase the Need for Risk-Advisory Brokerage
Wednesday, July 29, 2026
Clinical research insurance brokerage services in Latin America are moving beyond policy placement as trial designs become more complex. Sponsors are running oncology, rare disease, device, decentralized and first-in-human studies across regional markets, which changes the risk profile and insurance needs before enrollment begins. The region is attracting more research activity because sponsors want recruitment access and diversified trial footprints. Towards Healthcare estimates that the Latin America clinical trials market will grow from USD 5.0 billion in 2026 to USD 9.17 billion by 2035, while the region’s pharmaceutical contract manufacturing and research services mar
What Defines a Gold Standard in Early Cancer Detection Testing
Friday, June 12, 2026
Cancer screening decisions increasingly sit at the intersection of clinical urgency, payer scrutiny and patient access. For executives evaluating early cancer detection testing providers, speed and technological novelty alone are no longer sufficient differentiators. The more important question is whether a test can provide clinically actionable direction before symptoms emerge, invasive diagnostics become necessary, or late-stage imaging begins to dictate the care pathway. In life science technology, a key indicator for value is the timeliness of the signal detection, its specificity of guidance to the next clinical step and its adaptability to diverse populations without increased cost
